Markets:

Overview

News

Currencies

International

Treasuries

AbbVie (NY:ABBV)

208.84 -6.14 (-2.86%)

Official Closing Price Updated: 7:00 PM EDT, Apr 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9

...

95 96 Next >

Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation

Today 9:51 EDT

By Financial Research Feature April 3, 2026 Introduction In the high-stakes arena of global biotechnology, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has long stood as a paragon of scientific...

Via Finterra

2 Healthcare Dividend Stocks to Buy as the Tech-Heavy Nasdaq Dips Below Correction Territory ↗

April 02, 2026

Dividend payers might become more popular if the recent volatility continues. These two stocks are great picks to weather the storm.

Via The Motley Fool

Topics Economy Retirement Stocks

Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer

April 02, 2026

BRUSSELS — In a major victory for one of the world’s leading pharmaceutical giants, the European Commission (EC) has officially granted marketing authorization for Merck & Co. (NYSE: MRK) blockbuster...

Via MarketMinute

Topics Intellectual Property

AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know

April 02, 2026

What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa...

Via StockStory

Topics Government Stocks World Trade

The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future

April 01, 2026

As we enter the second quarter of 2026, Johnson & Johnson (NYSE: JNJ) stands as a starkly different entity than the consumer-facing conglomerate that defined the 20th century. Having successfully shed...

Via Finterra

Topics Artificial Intelligence Earnings Economy

Gilead Sciences Acquires Ouro Medicines for $2.2 Billion to Lead 'Immune Reset' Revolution

March 31, 2026

In a move that signals a decisive shift in the treatment of chronic autoimmune conditions, Gilead Sciences (NASDAQ:GILD) announced on March 23, 2026, its definitive agreement to acquire Ouro Medicines...

Via MarketMinute

Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally

March 31, 2026

In a month characterized by macroeconomic headwinds and a broader cooling of the biotechnology sector, Corcept Therapeutics (NASDAQ: CORT) has emerged as a definitive outlier. While the S&P Biotech ETF...

Via MarketMinute

Topics ETFs Intellectual Property Stocks

Merck Just Made a Big Bet on a New Cancer Growth Engine ↗

March 31, 2026

Via MarketBeat

This Top ETF Recently Added a Healthy Dose of These High-Yielding Dividend Stocks ↗

March 30, 2026

The Schwab U.S. Dividend Equity ETF is increasing its allocation to healthcare dividend stocks.

Via The Motley Fool

Topics ETFs Stocks

1 Reason Eli Lilly Stock Is Still a Buy ↗

March 28, 2026

Eli Lilly is much more than just a weight loss stock.

Via The Motley Fool

Topics Artificial Intelligence

Eli Lilly Shares Slip Despite Positive Eczema Trial Results: Why the Market Reacted Coolly

March 27, 2026

INDIANAPOLIS – In a move that has left some retail investors scratching their heads, shares of Eli Lilly and Company (NYSE:LLY) have trended lower this week, despite the pharmaceutical giant releasing...

Via MarketMinute

Here's How Many Shares of AbbVie (ABBV) Stock You'd Need for $10,000 in Yearly Dividends ↗

March 27, 2026

The stock has averaged annual gains of 16.2% over the past decade, and it sports a generous dividend yield, too.

Via The Motley Fool

Topics Intellectual Property

The 15-Minute Breakthrough: A Deep Dive into GH Research (GHRS) and the Future of Rapid-Acting Psychedelics

March 26, 2026

Today’s Date: March 26, 2026 Introduction As the global mental health crisis reaches unprecedented levels, the pharmaceutical industry has been forced to look beyond traditional SSRIs toward more...

Via Finterra

Topics Cannabis Initial Public Offering Intellectual Property

The Fed Is Worried About Trump-Fueled Inflation. Are Your Stocks Safe? ↗

March 25, 2026

Investors should be prepared in case inflation remains higher than expected.

Via The Motley Fool

Topics Economy Government World Trade

What Is Considered a Good Stock Dividend? 2 Healthcare Stocks Fit the Bill. ↗

March 24, 2026

This pair busts the myth of the sector being a desert for income investors.

Via The Motley Fool

Topics Intellectual Property

Bristol-Myers Squibb Shares Jump 3.3% on Robust 2026 Guidance and High Dividend Yield

March 23, 2026

Shares of pharmaceutical giant Bristol-Myers Squibb (NYSE:BMY) climbed 3.3% in early trading on Monday, March 23, 2026, after the company issued a surprisingly robust financial outlook for the fiscal...

Via MarketMinute

Topics Economy Initial Public Offering Intellectual Property

Why AbbVie Stock Looks Like a Dirt Cheap Buy Right Now ↗

March 23, 2026

AbbVie has strong financials, a great dividend, and its stock trades at a modest valuation.

Via The Motley Fool

Topics ETFs Intellectual Property

FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market

March 23, 2026

In a landmark decision for the dermatology sector, the U.S. Food and Drug Administration (FDA) has officially approved ICOTYDE™ (icotrokinra), a first-of-its-kind oral peptide for the treatment of...

Via MarketMinute

Best Healthcare Stocks to Buy After the Market Pullback ↗

March 20, 2026

They have the means to recover from recent setbacks.

Via The Motley Fool

The Smartest Dividend Stocks to Buy With $2,000 Right Now ↗

March 20, 2026

These great dividend stocks are especially attractive in the current market conditions.

Via The Motley Fool

Topics Energy Intellectual Property

AbbVie Shares Retreat to Multi-Month Lows Amid Competitive Headwinds and Technical Breakdown

March 18, 2026

The pharmaceutical giant AbbVie (NYSE: ABBV) experienced a sharp decline on Wednesday, March 18, 2026, as its stock price tumbled to its lowest level since mid-2025. Shares of the Illinois-based...

Via MarketMinute

Topics ETFs Economy Intellectual Property

Top S&P500 movers in Wednesday's session ↗

March 18, 2026

Via Chartmill

Wednesday's session: top gainers and losers in the S&P500 index ↗

March 18, 2026

Via Chartmill

What's Going On With AbbVie Stock Today? ↗

March 18, 2026

Shares of AbbVie Inc. (NASDAQ: ABBV) are moving lower Wednesday. The stock appears to be trending down after a competitor announced significant progress made on a treatment for plaque psoriasis.

Via Benzinga

Wednesday's session: gap up and gap down stock in the S&P500 index ↗

March 18, 2026

Via Chartmill

My Top 3 Dividend Kings to Buy for March 2026 ↗

March 17, 2026

Only the best dividend stocks can achieve "king" status.

Via The Motley Fool

My 5 Favorite Dividend Stocks to Buy Right Now ↗

March 15, 2026

There are lots of choices, but these are at the top of my list.

Via The Motley Fool

Topics Retirement

Concorde Financial Exits Howard Hughes Holdings, Developer of Large Sun Belt Communities ↗

March 13, 2026

Howard Hughes owns large land holdings in fast-growing markets such as Las Vegas, Houston, and Phoenix, where it has developed master-planned communities over many years. Investors will watch whether...

Via The Motley Fool

Topics Regulatory Compliance

The Best Dividend Stocks to Buy and Hold Forever ↗

March 12, 2026

They are relatively safe wealth compounders.

Via The Motley Fool

Topics Intellectual Property

Market Downturn: 2 Stocks to Buy and Hold Through Any Storm ↗

March 11, 2026

These companies are highly unlikely to go under, no matter what happens.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

95 96 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

AbbVie (NY:ABBV)

All News about AbbVie

Starting at $3.75/week.

Subscribe Today